Your browser is no longer supported. Please, upgrade your browser.
Settings
FOLD Amicus Therapeutics, Inc. daily Stock Chart
FOLD [NASD]
Amicus Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.17 Insider Own0.90% Shs Outstand254.37M Perf Week6.06%
Market Cap2.49B Forward P/E- EPS next Y-1.10 Insider Trans-6.71% Shs Float252.62M Perf Month-3.83%
Income-442.20M PEG- EPS next Q-0.33 Inst Own- Short Float11.73% Perf Quarter-13.66%
Sales131.40M P/S18.97 EPS this Y-0.50% Inst Trans7.79% Short Ratio8.43 Perf Half Y-29.14%
Book/sh2.52 P/B3.89 EPS next Y26.40% ROA-53.40% Target Price18.23 Perf Year-17.44%
Cash/sh2.26 P/C4.33 EPS next 5Y- ROE-97.90% 52W Range8.27 - 14.61 Perf YTD2.30%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-49.50% 52W High-32.95% Beta1.57
Dividend %- Quick Ratio7.00 Sales past 5Y202.00% Gross Margin86.20% 52W Low18.50% ATR0.44
Employees508 Current Ratio7.10 Sales Q/Q107.00% Oper. Margin- RSI (14)41.66 Volatility4.48% 4.04%
OptionableYes Debt/Eq0.25 EPS Q/Q-8.30% Profit Margin- Rel Volume0.53 Prev Close9.79
ShortableYes LT Debt/Eq0.25 EarningsAug 08 BMO Payout- Avg Volume3.51M Price9.80
Recom1.70 SMA20-0.90% SMA50-12.64% SMA200-17.34% Volume1,863,601 Change0.10%
Jun-17-19Initiated H.C. Wainwright Buy $18
Jun-05-19Reiterated Cantor Fitzgerald Overweight $20 → $19
Apr-05-19Initiated Janney Buy
Jan-30-19Initiated Cantor Fitzgerald Overweight $20
Oct-29-18Initiated Citigroup Neutral $12
Aug-17-18Downgrade Chardan Capital Markets Buy → Neutral $18 → $15
Oct-06-17Resumed Goldman Neutral
Sep-13-17Reiterated Chardan Capital Markets Buy $17.50 → $16.50
Aug-10-17Reiterated Chardan Capital Markets Buy $12.50 → $17.50
Jan-24-17Upgrade Robert W. Baird Neutral → Outperform $7 → $10
May-18-16Initiated BofA/Merrill Buy $10
Apr-14-16Initiated Robert W. Baird Neutral $9
Apr-12-16Reiterated Chardan Capital Markets Buy $10 → $15
Sep-16-15Downgrade Chardan Capital Markets Buy → Neutral $17
Jun-16-15Reiterated Chardan Capital Markets Buy $14 → $17.50
May-29-15Initiated Chardan Capital Markets Buy $14
Dec-20-12Reiterated Canaccord Genuity Buy $11 → $6
Dec-20-12Downgrade Capstone Investments Buy → Hold $3
Nov-01-12Initiated Capstone Investments Buy $7
Apr-06-10Initiated Canaccord Adams Buy
Sep-07-19 09:30AM  Why Is Amicus Therapeutics (FOLD) Down 18.9% Since Last Earnings Report? Zacks
Sep-04-19 07:00AM  Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019 GlobeNewswire
Aug-21-19 11:53AM  Edited Transcript of FOLD earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-19-19 09:35AM  Is Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) CEO Overpaid Relative To Its Peers? Simply Wall St.
Aug-12-19 10:59AM  Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View Zacks
Aug-10-19 01:30AM  Amicus Therapeutics Inc (FOLD) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 09:25AM  Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM  Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates GlobeNewswire
Aug-02-19 07:00AM  Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina GlobeNewswire -6.43%
Aug-01-19 10:33AM  Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for Zacks
06:00AM  Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease GlobeNewswire
Jul-29-19 07:00AM  Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019 GlobeNewswire
Jul-22-19 01:07PM  New Jersey biotech firm to open Lake Nona office, lab American City Business Journals
Jul-04-19 01:39PM  If You Had Bought Amicus Therapeutics (NASDAQ:FOLD) Stock Five Years Ago, You Could Pocket A 227% Gain Today Simply Wall St.
11:51AM  Why Amicus Therapeutics' Stock Perked Up in June Motley Fool
Jul-02-19 07:30AM  Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing GlobeNewswire
Jul-01-19 07:00AM  Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration GlobeNewswire
Jun-19-19 09:59PM  Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy? Insider Monkey
Jun-13-19 07:30AM  Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership GlobeNewswire
Jun-12-19 05:49PM  New Jersey biotech firm scales back Lake Nona plans American City Business Journals
08:44AM  2 Small Biotechs With Sagging Shares but Promising Prospects TheStreet.com
Jun-07-19 09:30AM  Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report? Zacks
Jun-05-19 11:25AM  Edited Transcript of FOLD earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
Jun-04-19 04:01PM  Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock GlobeNewswire +7.82%
Jun-03-19 07:00AM  Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences GlobeNewswire
May-31-19 07:34AM  The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering Benzinga
May-30-19 09:00PM  Amicus Therapeutics Prices Underwritten Offering of Common Stock GlobeNewswire -9.79%
04:29PM  Why NIO, PVH, and Amicus Therapeutics Slumped Today Motley Fool
02:11PM  Here's Why Amicus Therapeutics Fell as Much as 15.6% Today Motley Fool
10:34AM  2 Ultra-High-Growth Biotech Stocks to Buy Now Motley Fool
07:33AM  The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug Benzinga
May-29-19 04:14PM  Amicus Therapeutics Announces Public Offering of Common Stock GlobeNewswire
11:36AM  Amicus, Penn expand gene therapy collaboration in a big way American City Business Journals
06:30AM  Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration GlobeNewswire
May-13-19 05:00PM  Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors GlobeNewswire -5.18%
May-10-19 07:00AM  Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference GlobeNewswire
May-09-19 03:21PM  Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1 Zacks
May-08-19 04:23PM  Amicus Therapeutics Inc (FOLD) Q1 2019 Earnings Call Transcript Motley Fool
08:25AM  Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:24AM  Amicus Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates GlobeNewswire
May-03-19 09:51AM  What's in Store for Catalyst Pharma (CPRX) Q1 Earnings? Zacks
May-01-19 10:33AM  Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-30-19 08:00PM  3 Growth Stocks to Buy and Hold for the Next 50 Years Motley Fool
08:06AM  The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering Benzinga
06:00AM  Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting GlobeNewswire
Apr-25-19 07:00AM  Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-15-19 03:36PM  FOLD Stock Could See a Surge Soon, Says Signal Schaeffer's Investment Research
12:00PM  Amicus Therapeutics to Present Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting GlobeNewswire
Apr-10-19 12:47PM  What Investors Should Know About Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Financial Strength Simply Wall St.
Apr-05-19 12:27PM  Janney: Amicus Therapeutics Has Significant Upside From Gene Therapy Pipeline Benzinga
Mar-30-19 09:30AM  Amicus Therapeutics (FOLD) Up 12.4% Since Last Earnings Report: Can It Continue? Zacks
Mar-29-19 07:10AM  Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-20-19 02:09PM  Edited Transcript of FOLD earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
07:00AM  Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200 GlobeNewswire
Mar-07-19 02:52PM  Amicus Therapeutics Looks Impressive If it Can Rally Above $18 TheStreet.com
Mar-06-19 02:39PM  Will Amicus Therapeutics, Inc.s (NASDAQ:FOLD) Earnings Grow In The Years Ahead? Simply Wall St.
Mar-01-19 11:59AM  Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018 Zacks +15.04%
Feb-28-19 12:04PM  Amicus Therapeutics Inc (FOLD) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates GlobeNewswire
06:30AM  Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-19 07:32AM  N.J. biotech firm expanding to Philadelphia, creating 200 new jobs American City Business Journals
07:00AM  Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia GlobeNewswire
Feb-25-19 09:02AM  What's in Store for Universal Health (UHS) Q4 Earnings? Zacks +5.87%
04:00AM  U.S. FDA Grants Breakthrough Therapy Designation (BTD) to Amicus AT-GAA in Late Onset Pompe Disease GlobeNewswire
Feb-22-19 04:36PM  What's in Store for Teladoc's (TDOC) Q4 Earnings? Zacks
Feb-21-19 10:31AM  Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Feb-20-19 09:32AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Offing? Zacks
Feb-13-19 07:30AM  New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-12-19 07:00AM  Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019 GlobeNewswire
Feb-11-19 04:51PM  Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-05-19 04:01PM  Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium GlobeNewswire -5.22%
Feb-04-19 10:38AM  2 Small-Cap Stocks That Are Still a Bargain TheStreet.com
Jan-28-19 08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and ACADIA Pharmaceuticals ACCESSWIRE
Jan-24-19 10:08AM  Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition Zacks
Jan-18-19 07:00AM  Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium 2019 GlobeNewswire
Jan-16-19 08:05AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics ACCESSWIRE
Jan-15-19 09:00AM  Is Amicus Therapeutics' Sharp Reversal Warranted? Motley Fool +5.36%
Jan-10-19 07:30AM  Research Report Identifies FedEx, Amicus Therapeutics, National HealthCare, Allegion, Horizon Global, and PICO with Renewed Outlook  Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-07-19 07:00AM  Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance GlobeNewswire
Jan-03-19 04:01PM  Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
07:00AM  Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease GlobeNewswire
Dec-20-18 07:00AM  Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease GlobeNewswire -5.11%
Dec-19-18 04:01PM  Amicus Therapeutics Announces Executive Team Updates GlobeNewswire -6.47%
Dec-12-18 10:58AM  Should You Worry About Amicus Therapeutics, Inc.s (NASDAQ:FOLD) CEO Pay? Simply Wall St.
Dec-11-18 04:01PM  Amicus Therapeutics Awarded United Kingdom Prix Galien Medal for Galafold® (Migalastat) GlobeNewswire
07:05AM  Today's Research Reports on Trending Tickers: Immunomedics and Amicus Therapeutics ACCESSWIRE
Dec-10-18 03:21AM  Amicus Therapeutics, Inc. (FOLD) Hedge Funds Are Snapping Up Insider Monkey +6.96%
Dec-04-18 07:35AM  Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage Fundamental Analysis, Key Performance Indications GlobeNewswire -9.32%
Nov-29-18 07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Amicus Therapeutics ACCESSWIRE
Nov-20-18 07:52AM  Edited Transcript of FOLD earnings conference call or presentation 5-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 06:55AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen ACCESSWIRE -5.01%
Nov-12-18 07:00AM  Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Nov-05-18 08:45AM  Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:42AM  Amicus Therapeutics: 3Q Earnings Snapshot Associated Press
07:00AM  Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates GlobeNewswire
Oct-29-18 08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Geron ACCESSWIRE
07:00AM  Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018 GlobeNewswire
Oct-25-18 09:25AM  Recent Analysis Shows PennyMac Mortgage Investment Trust, Amicus Therapeutics, Children's Place, PLDT, NanoString Technologies, and Worthington Industries Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +5.08%
Oct-22-18 01:56PM  5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout InvestorPlace
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies; and a strategic manufacturing agreement with Catalent Biologics. The company has a strategic manufacturing collaboration with Thermo Fisher Scientific for conducting preclinical and clinical-stage gene therapy programs for CLN6, CLN3, and other Batten disease programs. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Crowley John FChairman & CEOSep 11Option Exercise3.8220,00076,400770,194Sep 13 05:09 PM
Crowley John FChairman & CEOSep 11Sale10.0520,000201,030750,194Sep 13 05:09 PM
WHITMAN BURKE WDirectorAug 23Buy10.074,94549,79621,612Aug 27 07:59 PM
Crowley John FChairman & CEOAug 01Option Exercise3.8220,00076,400770,194Aug 02 04:40 PM
Crowley John FChairman & CEOAug 01Sale12.5420,000250,736750,194Aug 02 04:40 PM
Crowley John FChairman & CEOJul 01Option Exercise3.8220,00076,400770,194Jul 02 05:18 PM
Crowley John FChairman & CEOJul 01Sale12.4720,000249,462750,194Jul 02 05:18 PM
RAAB MICHAELDirectorJun 03Option Exercise7.155,00035,75013,895Jun 04 04:35 PM
Crowley John FChairman & CEOJun 03Option Exercise3.8220,00076,400770,399Jun 04 04:34 PM
Crowley John FChairman & CEOJun 03Sale11.1520,000223,072750,399Jun 04 04:34 PM
RAAB MICHAELDirectorJun 03Sale11.165,00055,7768,895Jun 04 04:35 PM
Crowley John FChairman & CEOMay 01Option Exercise3.8220,00076,400770,399May 02 04:22 PM
Crowley John FChairman & CEOMay 01Sale13.5120,000270,154750,399May 02 04:22 PM
Barth JayChief Medical OfficerApr 05Option Exercise2.2950,000114,500179,767Apr 08 04:52 PM
Barth JayChief Medical OfficerApr 05Sale14.2050,000710,195129,767Apr 08 04:52 PM
Crowley John FChairman & CEOApr 01Option Exercise3.5020,00069,968688,081Apr 03 06:29 PM
Crowley John FChairman & CEOApr 01Sale13.6320,000272,626668,081Apr 03 06:29 PM
Crowley John FChairman & CEOMar 01Option Exercise3.5420,00070,848688,081Mar 05 05:47 PM
Crowley John FChairman & CEOMar 01Sale13.6020,000271,979668,081Mar 05 05:47 PM
Barth JayChief Medical OfficerFeb 25Option Exercise2.7070,000188,725173,497Feb 27 05:30 PM
Barth JayChief Medical OfficerFeb 25Sale12.5270,000876,134129,767Feb 27 05:30 PM
Crowley John FChairman & CEOFeb 01Option Exercise3.8220,00076,400688,081Feb 05 06:10 PM
Crowley John FChairman & CEOFeb 01Sale12.1220,000242,320668,081Feb 05 06:10 PM
Campbell Bradley LChief Operating OfficerJan 22Option Exercise10.3636,000372,960275,360Jan 24 05:06 PM
Campbell Bradley LChief Operating OfficerJan 22Sale11.8136,000425,135239,360Jan 24 05:06 PM
Do HungChief Science OfficerJan 16Option Exercise4.8235,024168,749474,937Jan 17 08:48 PM
Do HungChief Science OfficerJan 16Sale12.0536,669441,861438,268Jan 17 08:48 PM
Crowley John FChairman & CEOJan 15Option Exercise10.36103,5001,072,260771,581Jan 17 08:47 PM
Do HungChief Science OfficerJan 15Option Exercise3.958,20032,430456,513Jan 17 08:48 PM
Do HungChief Science OfficerJan 15Sale12.0016,600199,200439,913Jan 17 08:48 PM
Crowley John FChairman & CEOJan 15Sale11.71103,5001,212,296668,081Jan 17 08:47 PM
Baird William D IIIChief Financial OfficerOct 15Option Exercise2.4510,00024,500127,622Oct 17 06:28 PM
Baird William D IIIChief Financial OfficerOct 15Sale12.2310,000122,275117,622Oct 17 06:28 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 03Buy12.6930,000380,70020,724,424Oct 05 08:36 AM
PERCEPTIVE ADVISORS LLC10% OwnerSep 24Buy12.4520,000249,00020,694,424Oct 05 08:36 AM
PERCEPTIVE ADVISORS LLC10% OwnerSep 21Buy12.5350,000626,50020,674,424Sep 25 08:30 AM